1. Home
  2. SBFM vs MBIO Comparison

SBFM vs MBIO Comparison

Compare SBFM & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunshine Biopharma Inc.

SBFM

Sunshine Biopharma Inc.

HOLD

Current Price

$2.11

Market Cap

4.7M

Sector

Health Care

ML Signal

HOLD

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.69

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBFM
MBIO
Founded
2006
2015
Country
United States
United States
Employees
50
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
5.6M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
SBFM
MBIO
Price
$2.11
$0.69
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
129.1K
50.7K
Earning Date
04-03-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$40.47
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.53
52 Week High
$3.05
$7.00

Technical Indicators

Market Signals
Indicator
SBFM
MBIO
Relative Strength Index (RSI) 57.53 50.29
Support Level $2.01 $0.67
Resistance Level $2.13 $0.82
Average True Range (ATR) 0.14 0.06
MACD -0.05 -0.00
Stochastic Oscillator 24.45 45.35

Price Performance

Historical Comparison
SBFM
MBIO

About SBFM Sunshine Biopharma Inc.

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: